Literature DB >> 25761845

Medical cannabis vs. synthetic cannabinoids: What does the future hold?

D Bolognini1,2, R A Ross1.   

Abstract

The medical use of cannabis has an intricate therapeutic history that finds its roots in ancient China (∼2700 BC). The main psychoactive component of cannabis, Δ(9) -tetrahydrocannabinol (Δ(9) -THC), was discovered in 1964. This was a significant breakthrough, as it allowed the generation of synthetic analogs of Δ(9) -THC, the discovery of cannabinoid receptors, and the generation of synthetic small molecules. Despite this, today there is still a paucity of drugs that target the cannabinoid system.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25761845     DOI: 10.1002/cpt.107

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.

Authors:  Dan L McElroy; Andrew J Roebuck; Gavin A Scott; Quentin Greba; Sumanta Garai; Eileen M Denovan-Wright; Ganesh A Thakur; Robert B Laprairie; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2021-01-13       Impact factor: 4.530

Review 2.  Systematic Review of the Use of Phytochemicals for Management of Pain in Cancer Therapy.

Authors:  Andrew M Harrison; Fabrice Heritier; Bennett G Childs; J Michael Bostwick; Mikhail A Dziadzko
Journal:  Biomed Res Int       Date:  2015-10-20       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.